Oxytocin and fetal membranes in preterm labor: current concepts and clinical implication

References

• Robinson JN, Regan JA, Norwitz ER. The epidemi-ology of preterm labor. Semin Perinatol 2001;25: 204–14
   Google Scholar
• Amon E. Premature labor. In Reece E, ed. Medicine of the Fetus & Mother. Philadelphia: JB Lippincott, 1992:1398–429
   Google Scholar
• World Health Organization. The incidence of low birth weight: a critical review ofavailable information. World Health Stat Q 1980;33:197–224
   PubMedGoogle Scholar
• Joseph K, Kramer M., Marcoux S, et al. Determinants of preterm birth rates in Canada from 1981 through 1983 and from 1992 through 1994. N Engl J Med 1998;339:1434–9
   PubMed Web of Science ®Google Scholar
• Villar J, Ezcurra E. Preterm delivery syndrome: the unmet need. New perspectives for the effective treatment of preterm labour — an international con-sensus. Res Clin Forums 1994;16:9–38
   Google Scholar
• Ingemarsson I. Mother — the forgotten patient. In: EAGO/EBCOG 16th European Congress of Obstetrics and Gynaecology; Malmo, Sweden, 2001
   Google Scholar
• Chibbar R, Miller F, Mitchell B. Synthesis of oxytocin in amnion, chorion and decidua may influence the timing of human parturition. J Clin Invest 1993;91:185–92
   Google Scholar
• Lemancewicz A, Laudanska H, Laudanski T, et al. Permeability of fetal membranes to calcium and magnesium: possible role in preterm labour. Hum Reprod 2000;15:2018–22
   Google Scholar
• Carbillon L, Uzan M, Challier JC, et al. Fetal—placental and decidual—placental units: role of endocrine and paracrine regulations in parturition. Fetal Diagn Ther 2000;15:308–18
   Google Scholar
• Germain A, Smith J, MacDonald P, et al. Human fetal membrane contribution to the prevention of parturition: uterotonin degradation. J Clin Endocrinol Metab 1994;78:463–70
   PubMed Web of Science ®Google Scholar
• MacDonald P, Casey M. The accumulation of prostaglandins (PG) in amniotic fluid is an aftereffect of labor and not indicative of a role for PGE2 and PGF2alpha in the initiation of human parturition. J Clin Endocrinol Metab 1993;76:1332–9
   PubMed Web of Science ®Google Scholar
• Sladek S, Magness R, Conrad K. Nitric oxide and pregnancy. Am J Physiol 1997;41:R441–63
   Google Scholar
• Nanno H, Sagawa N, Itoh H. Nitric oxide metabolite concentrations in maternal plasma decrease during parturition: possible transient down-regulation of nitric oxide synthesis. Mol Hum Reprod 1998;4:609–16
   Google Scholar
• Yallampalli C, Buhimschi I, Chwallisz K, et al. Preterm birth in rats produced by synergistic action of nitric oxide inhibitor (NG-nitro-L-arginine methyl ester) and an antiprogestin (onapristone). Am J Obstet Gynecol 1996;175:207–12
   Google Scholar
• Buhimschi I, Yallampalli C, Dong Y, et al. Involve-ment of a nitric oxide guanosine monophosphate pathway in control of human uterine contractility during pregnancy. Am J Obstet Gynecol 1995;172: 1577–84
   PubMed Web of Science ®Google Scholar
• Dennes W, Slater D, Bennett P. Nitric oxide synthase mRNA expression in human fetal membranes: a possible role in parturition. Biochem Biophys Res Commun 1997;233:276–8
   Google Scholar
• Knowles R, Moncada S. Nitric oxide synthases in mammals. Biochem J 1994;298:249–58
   PubMed Web of Science ®Google Scholar
• Pearson P, Evora P, Seccombe J, et al. Hypo-magnesemia inhibits nitric oxide release from coronary endothelium: protective role of magnesium infusion after cardiac operations. Ann Thorac Surg 1998;65:967–72
   PubMed Web of Science ®Google Scholar
• Motta A, Chaud M, de Gimeno M. Regulation by nitric oxide of prostaglandin E synthesis and spontaneous motility in rat uterine tissue. Prostaglandins Leukot Essent Fatty Acids 1998;58:333–8
   Google Scholar
• Dale H. On some physiologic action of ergot.JPhysiol (London) 1906;34:163
   Google Scholar
• Pierce J, du Vigneaud V. Studies on potency of oxytocic materials from beef posterior pituitary lobes. J Biol Chem 1950;186:77
   Google Scholar
• Simons CJ, Clancy T, Quan R, et al. The oxytocin receptor gene (OXTR) localizes to human chromo-somes 3p25 by fluorescence in situ hybridisation and PCR analysis of somatic cell hybrids. Genomics 1995; 26:623–5
   Google Scholar
• Michelini S, Urbanek M, Dean M, et al. Poly-morphism and genetic mapping of the human oxytocin gene on chromosome 3. Am J Med Genet 1995;45:73–7
   Google Scholar
• Zeeman G, Khan-Dawood F, Dawood M. Oxytocin and its receptor in pregnancy and parturition: current concepts and clinical implications. Obstet Gynecol 1997;89:873–83
   Google Scholar
• Kimura T, Takemura M, Nomura S, et al. Expression of oxytocin receptor in human pregnant myo-metrium. Endocrinology 1996;137:7780–5
   Google Scholar
• Benedetto M, De Cicco F, Rosiello F, et al. Oxytocin receptors in human fetal membranes at term and during labor. J Steroid Biochem 1990;35:205–8
   Google Scholar
• Bossmar T, Akerlund M, Fantoni G, et al. Receptors for and myometrial responses to oxytocin and vasopressin in preterm and term human pregnancy: effect of the oxytocin antagonist atosiban. Am J Obstet Gynecol 1994;171:1634–42
   PubMed Web of Science ®Google Scholar
• Zicari A, Ticconi C, Realacci M, et al. Hormonal regulation of cytokine release by human fetal membranes at term gestation: effects of oxytocin, hydrocortisone and progesterone on tumour necrosis factor-alpha and transforming growth factor-beta 1 output. J Reprod Immunol 2002;56:123–36
   Google Scholar
• Schmid B, Wong S, Mitchell BF. Transcriptional regulation of oxytocin receptor by interleukin-1 beta and interleukin-6. Endocrinology 2001;142: 1380–5
   Google Scholar
• Valenzuela G, Hewitt C, Ducsay C. Endothelin-1 potentiates the in vitro contractile response of pregnant human myometrium to oxytocin. Am J Obstet Gynecol 1995;172: 1573–6
   Google Scholar
• Akerlund M. Involvement of oxytocin and vasopressin in the pathophysiology of preterm labor and primary dysmenorrhea. Prog Brain Res 2002; 139:359–65
   PubMed Web of Science ®Google Scholar
• Zingg H, Rozen F, Chu K, et al. Oxytocin and oxytocin receptor gene expression in the uterus. Recent Prog Horm Res 1995;50:255–73
   Google Scholar
• Akerlund M, Bossmar T, Brouard R, et al. Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women. Br J Obstet Gynaecol 1999;106:1047–53
   PubMedGoogle Scholar
• Ivanisevic M, Behrens O, Helmer H, et al. Vasopressin receptors in human pregnant myometrium and decidua: interactions with oxytocin and vasopressin agonists and antagonists. Am J Obstet Gyencol 1989; 161:1637–43
   Google Scholar
• Thornton S, Baldwin P, Harris P, et al. The role of arginine vasopressin in human labour: functional studies, fetal production and localisation of Via receptor mRNA. Br J Obstet Gynaecol 2002;190: 57–62
   Google Scholar
• Helmer H, Hackl T, Schneeberger C, et al. Oxytocin and vasopressin la receptor gene expression in the cycling or pregnant human uterus. Am J Obstet Gynecol 1998;179:1572–8
   Google Scholar
• Moutquin J, Sherman D, Cohen H, et al. Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multi-center effectiveness and safety study. Am J Obstet Gynecol 2000;182:1191–9
   PubMed Web of Science ®Google Scholar
• French/Australian Atosiban Investigators Study Group. Treatment ofpreterm labor with the oxytocin antagonist atosiban: a double blind, controlled comparison with salbutamol. Eur J Obstet Gynecol Reprod Biol 2001;98: 177–85
   Google Scholar
• The World wide Atosiban versus Beta-agonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agents in the treatment of preterm labour. Br J Obstet Gynaecol 2001;108:133–42
   Google Scholar
• Goodwin T, Paul R, Silver H, et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. Am J Obstet Gynecol 1994; 170:474–8
   PubMed Web of Science ®Google Scholar
• Akerlund M, Hauksson A, Lundin S, et al. Vasotocin analogues which competitively inhibit vasopressin stimulated uterine activity in healthy women. Br J Obstet Gynaecol 1986;93:22–7
   Google Scholar
• Akerlund M. Can primary dysmenorrhea be alleviated by vasopressin antagonists? Results of a pilot study. Acta Obstet Gynecol Scand 1987;66: 459–61
   PubMed Web of Science ®Google Scholar
• Hauksson A, Akerlund M, Melin P. Uterine blood flow and myometrial activity at menstruation, and the action of vasopressin and a synthetic antagonist. Br J Obstet Gynaecol 1988;95:898–904
   Google Scholar
• Akerlund M, Stromberg P, Hauksson A, et al. Inhibition ofuterine contractions ofpremature labour with an oxytocin analogue. Results from a pilot study. Br J Obstet Gynaecol 1987 ;94:1040–4
   PubMed Web of Science ®Google Scholar
• Andersen L, Lyndrup J, Akerlund M, et al. Oxytocin receptor blockade: a new principle in the treatment of preterm labor? Am J Perinatol 1989;6:196–9
   PubMed Web of Science ®Google Scholar
• Eriksson H, Bjorgell P, Akerlund M, et al. Effects of a tocolytic oxytocin analogue on lipid and cardohydrate metabolism. Gynecol Obstet Invest 1990;29:97–100
   Google Scholar
• Lundin S, Broeders A. Melin P. Pharmacokinetic properties of the tocolytic agent [Mpa1,D-Tyr(Et)2, Thr4,Orn81-oxytocin (Antocin) in healthy volun-teers. Clin. Endocrinol 1993;39: 369–74
   Google Scholar
• Valenzuela G, Craig J, Bernhardt M, et al. Placental passage of the oxytocin antagonist atosiban. Am J Obstet Gynecol 1995;172:1304–6
   PubMed Web of Science ®Google Scholar
• Goodwin T, Valenzuela G, Silver H. Treatment of preterm labor with the oxytocin antagonist atosiban. Am J Perinatol 1996;13:143–6
   Google Scholar
• Steinwall M, Bossmar T RB, Laudanski T, et al. The effect of relcovaptan (SR 49059), an orally active vasopressin Via receptor antagonist, on uterine contractions in preterm labour. Br J Obstet Gynaecol 2003; in press
   Google Scholar